IONS
Ionis Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, Dec. 1, 12:14 PM
    • Goldman boosts its price target on AveXis (NASDAQ:AVXS) to $91 from $71 in a note to clients yesterday. Implied upside 62.5%.
    • "Given recent positive data from AVXS’ gene therapy AVXS-101 (Ph1) and IONS/BIIB’s antisense drug Spinraza (NDA filed), we conducted KOL due diligence to further elucidate the clinical presentation of the disease, physician awareness and outlook for market penetration. Our physician feedback reflects enthusiasm for both drugs; however, they appear to favor AVXS-101 given the recent motor milestone/survival data and the one-time potentially curative approach.
    • "We maintain our assumption of a 2020 U.S. launch but await clarity on the accelerated approval pathway on the current Ph1 data in 1H17."
    • Note: AVXS is -17% since a Nov. 17 negative article. Today it's down 5%.
    | Thu, Dec. 1, 12:14 PM | 42 Comments
  • Wed, Nov. 9, 12:42 PM
    | Wed, Nov. 9, 12:42 PM
  • Wed, Nov. 9, 11:06 AM
    | Wed, Nov. 9, 11:06 AM | 5 Comments
  • Wed, Nov. 9, 9:51 AM
    • Ionis Pharmaceuticals (IONS +13.9%) Q3 results: Revenues: $110.9M (+125.9%); Operating Income: $16.1M (+133.5%); Net Income: $7.4M (+120.7%); EPS: $0.06 (+120.0%); Quick Assets: $687.8M (-11.7%).
    • No guidance given.
    | Wed, Nov. 9, 9:51 AM | 2 Comments
  • Wed, Nov. 9, 7:02 AM
    • Ionis Pharmaceuticals (NASDAQ:IONS): Q3 EPS of $0.06 misses by $0.02.
    • Revenue of $110.93M (+125.8% Y/Y) misses by $2.16M.
    • Press Release
    | Wed, Nov. 9, 7:02 AM | 5 Comments
  • Tue, Nov. 8, 5:30 PM
  • Mon, Nov. 7, 12:44 PM
    | Mon, Nov. 7, 12:44 PM
  • Mon, Nov. 7, 11:01 AM
    | Mon, Nov. 7, 11:01 AM | 1 Comment
  • Mon, Nov. 7, 9:17 AM
    | Mon, Nov. 7, 9:17 AM | 4 Comments
  • Mon, Nov. 7, 8:04 AM
    • Ionis Pharmaceuticals (NASDAQ:IONS) and worldwide licensee Biogen (NASDAQ:BIIB) are up 8% and 3%, respectively, premarket in response to the news that a Phase 3 clinical trial, CHERISH, assessing SPINRAZA (nusinersen) in patients with later-onset (consistent with Type 2) spinal muscular atrophy (SMA) met its primary endpoint at the interim analysis. The results showed children treated with nusinersen experienced a statistically significant improvement in motor function compared to those who did not receive treatment.
    • Biogen intends to share the data will global regulatory authorities as soon as feasible. It submitted marketing applications in the U.S. and Europe in late October, both under accelerated review. The company expects to launch SPINRAZA by year end or Q1 2017. Data from the Phase 3 ENDEAR study in infantile-onset SMA (Type 1) were included in the filings.
    • Nusinersen is an antisense drug designed to correct the splicing defect that causes SMA by increasing the production of fully functional SMN protein. Biogen licensed it from Ionis under their 2012 collaboration agreement. If approved, Ionis could earn up to $225M in total milestones in addition to mid-teen royalties.
    | Mon, Nov. 7, 8:04 AM | 16 Comments
  • Tue, Nov. 1, 9:21 AM
    • Ionis Pharmaceuticals (NASDAQ:IONS) perks up 2% premarket on light volume in response to its announcement of successful results from a Phase 2 clinical trial assessing antithrombotic candidate IONIS-FXIrx in patients with end stage renal disease (ESRD) on hemodialysis. Results showed statistically significant dose-dependent reductions in Factor XI activity with no clinically meaningful reductions in platelet levels and treatment-related significant bleeding events, a major risk in these patients.
    • The company says IONIS-FXIrx is the only antithrombotic in development that has shown the potential to separate anti-clotting activity from bleeding risk.
    • The Phase 2 study involved 43 ESRD patients receiving hemodialysis. Each received 200 mg or 300 mg of IONIS-FXIrx or placebo for 12 weeks. The mean percent reductions in FXI activity were 56% (p<0.001), 71% (p<0.001) and 4%, respectively. In addition, a decrease in severe clotting events in the dialysis circuit versus baseline was observed after six weeks in the treatment group. There were no clinically meaningful changes in laboratory values, including those related to liver function. IONIS-FXIrx was well-tolerated with no flu-like symptoms and no injection site reactions.
    • IONIS-FXIrx is an antisense drug that reduces the production of Factor XI, a key component of the coagulation pathway. High levels of Factor XI increase the risk of thrombosis (a clot inside a blood vessel).
    • The company is set to receive a $55M milestone payment from licensee Bayer (OTCPK:BAYRY) triggered by the review of the Phase 2 data and advancement to Phase 3.
    | Tue, Nov. 1, 9:21 AM | 26 Comments
  • Fri, Oct. 28, 9:44 AM
    • The FDA accepts under Priority Review Biogen's (BIIB -1.3%) New Drug Application (NDA) seeking approval of nusinersen for the treatment of spinal muscular atrophy (SMA). The European Medicines Agency has done the same, accepting the company's Marketing Authorization Application (MAA) under Accelerated Assessment status. Both shorten the review clock.
    • SMA is an inherited disorder characterized by the loss of motor neurons in the spinal cord and lower brain stem, leading to severe and progressive muscular atrophy and weakness. It is caused by a defect in or loss of the SMN1 gene which results in the insufficient production of survival motor neuron protein, essential for maintenance of motor neurons.
    • Nusinersen is an antisense drug designed to correct the splicing defect that causes SMA by increasing the production of fully functional SMN protein. Biogen licensed it from Ionis Pharmaceuticals (IONS -0.7%) under their 2012 collaboration agreement. If approved, Ionis could earn up to $225M in total milestones in addition to mid-teen royalties.
    • Biogen intends to market nusinersen under the brand name SPINRAZA.
    | Fri, Oct. 28, 9:44 AM | 10 Comments
  • Fri, Oct. 7, 11:57 AM
    • Ionis Pharmaceuticals (NASDAQ:IONS) upgraded to Outperform from Market Perform by BMO Capital. Price target raised to $48 (42% upside) from $42.
    • Catalyst Pharmaceuticals (NASDAQ:CPRX) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $4 (199% upside) from $1.
    • AmerisourceBergen (NYSE:ABC) upgraded to Market Outperform from Market Perform by Avondale Partners.
    • Alnylam Pharmaceuticals (NASDAQ:ALNY) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $40 (14% upside) from $107. Downgraded to Equal Weight from Overweight by Barclays. Price target lowered to $50 (42% upside) from $85. Downgraded to Neutral from Overweight by JPMorgan. Downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $36 (3% upside) from $38.
    • Merrimack Pharmaceuticals (NASDAQ:MACK) downgraded to Neutral from Overweight with a $5.75 (2% upside) price target by JPMorgan.
    • Iradimed (NASDAQ:IRMD) downgraded to Neutral from Buy by Roth Capital. Price target lowered to $11.50 (11% upside) from $28.
    • Trinity Biotech (NASDAQ:TRIB) downgraded to Equal Weight from Overweight by Stephens & Co.
    • Depomed (NASDAQ:DEPO) downgraded to Neutral from Buy by Mizuho Securities.
    • Align Technology (NASDAQ:ALGN) downgraded to Neutral from Overweight with a $96 (8% upside) price target by Baird.
    | Fri, Oct. 7, 11:57 AM | 16 Comments
  • Thu, Oct. 6, 6:46 AM
    • BMO Capital upgrades Ionis Pharma (NASDAQ:IONS) to Outperform from Market Perform following yesterday's news that Alnylam (NASDAQ:ALNY) had discontinued its Revusiran program after observing an imbalance of deaths in treated patients.
    • "We are increasing our TTR-Rx revenues in familial amyloidotic cardiomyopathy (FAC) and wild-type (wt) to reflect no competition, which is partly offset by a lower probability of success (45% from 50%), given similar drug mechanisms. Consequently, our price target increases to $48 from $42. We believe IONS shares could be pressured as investors perceive added risk to TTR-Rx. We recommend buying on weakness."
    • In pre-market trading, IONS is -1% and ALNY is -43%.
    | Thu, Oct. 6, 6:46 AM | 27 Comments
  • Wed, Oct. 5, 5:35 PM
    | Wed, Oct. 5, 5:35 PM
  • Mon, Sep. 26, 10:47 AM
    • Biogen (BIIB -0.7%) finalizes the rolling submission of its New Drug Application (NDA) with the FDA seeking approval of nusinersen for the treatment of spinal muscular atrophy (SMA) along with a request for Priority Review which, if granted, will shorten the review clock to six months from the usual 10 months.
    • The company plans to file a marketing application in Europe in the coming months.
    • SMA is an inherited disorder characterized by the loss of motor neurons in the spinal cord and lower brain stem, leading to severe and progressive muscular atrophy and weakness. It is caused by a defect in or loss of the SMN1 gene which results in the insufficient production of survival motor neuron protein, essential for maintenance of motor neurons.
    • Nusinersen is an antisense drug designed to correct the splicing defect that causes SMA by increasing the production of fully functional SMN protein. Biogen licensed it from Ionis Pharmaceuticals (IONS -1.3%) under their 2012 collaboration agreement. If approved, Ionis could earn up to $225M in total milestones in addition to mid-teen royalties.
    | Mon, Sep. 26, 10:47 AM | 17 Comments